In the Original Investigation, “Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial,”1 that was published online on April 25, 2019, and in the June 2019 issue of JAMA Oncology, there were inconsistences in the reported primary and secondary outcomes as indicated in the original trial protocol approved by the Institutional Review Board (IRB). An amended protocol with the correct outcomes was retrospectively approved by the IRB. In addition, there were numerical errors in the Table. A Letter to the Editor explains the inconsistencies, errors, and corrections.2 Corrections to address these inconsistencies and errors were made to the subtitle; Abstract; Methods, Results, and Discussion sections; the Table; and previous Figure 2 (which has been removed). A new Supplement 2 with the amended protocol has been added. The article has been corrected online.
References
- 1.Nguyen QN, Chun SG, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 component of a phase 2/3 trial. JAMA Oncol. 2019;5(6):872-878. doi: 10.1001/jamaoncol.2019.0192 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nguyen QN. Errors in reported primary and secondary outcomes and table numbers in a trial of radiotherapy for pain relief in patients with bone metastases. JAMA Oncol. Published online August 12, 2021 doi: 10.1001/jamaoncol.2021.3054 [DOI] [PubMed] [Google Scholar]